nach oben

Erschienen in:

01.05.2009 | Short Communication

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

verfasst von: Massimo Breccia, Daniela Cilloni, Laura Cannella, Caterina Stefanizzi, Agostino Tafuri, Angelo Fama, Michelina Santopietro, Giuseppe Saglio, Giuliana Alimena

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54:1–27PubMedCrossRef

Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRa fusion tyrosine kinase in hyper eosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 103:2879–2891PubMedCrossRef

Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473–478PubMedCrossRef

Schaller JL, Burkland GA (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3:9

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, De Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173–1179PubMedCrossRef

Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76:535–536PubMedCrossRef

Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondomi M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G (2007) WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukaemia. Leukemia 21:1442–1450PubMedCrossRef

Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22PubMedCrossRef

Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRa and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 348:1201–1214PubMedCrossRef

10.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyi AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A (2006) FIP1L1-PDGFRa in eosinophilic disorders: prevalence in routine clinical practice, long term experience with imatinib therapy and a critical review of the literature. Leuk Res 30:965–970PubMedCrossRef

11.

Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492PubMedCrossRef

12.

Klion AD, Robyn J, Maric I, Fu W, Schmid I, Lemery S, Noel P, Law MA, Hatsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood 110:3352–3356CrossRef

13.

Helbig G, Holowiecka SB, Majewski M, Calbecka M, Gajkowska G, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Holowiecki J (2008) A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRa-expressing patients. Br J Haematol 141:200–204PubMedCrossRef

Titel: Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose
verfasst von: Massimo Breccia
Daniela Cilloni
Laura Cannella
Caterina Stefanizzi
Agostino Tafuri
Angelo Fama
Michelina Santopietro
Giuseppe Saglio
Giuliana Alimena
Publikationsdatum: 01.05.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0858-8

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie